BioTuesdays

Category - Markets

Fate Therapeutics
Markets

SVB Leerink starts Fate Therapeutics at OP; PT $20

SVB Leerink launched coverage of Fate Therapeutics (NASDAQ:FATE) with an “outperform” rating and $20 price target. The stock closed at $16.71 on March 27. Analyst Daina Graybosch writes that Fate is at the forefront of...

March 28, 2019
Affimed
Markets

SVB Leerink starts Affimed at OP; PT $8

SVB Leerink initiated coverage of Affimed NV (NASDAQ:AFMD) with an “outperform” rating and $8 price target. The stock closed at $4.17 on March 27. “Our positive view is fuelled by the potential of the company’s novel...

March 28, 2019
Atossa Genetics
Markets

Maxim ups Atossa Genetics PT to $9 from $5

Maxim Group raised its price target for Atossa Genetics (NASDAQ:ATOS) to $9 from $5 after the Institutional Review Board approved the use of oral endoxifen as a post-mastectomy treatment in pre-menopausal, estrogen...

March 26, 2019
Conatus
Markets

Roth cuts Conatus Pharma to neutral with PT of $1.70

Roth Capital Partners downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “neutral” with a price target of $1.70 after the company’s ENCORE-NF trial failed to meet its primary endpoint of an improvement of fibrosis...

March 26, 2019
Recro Pharma
Markets

Roth cuts Recro Pharma to neutral with PT $7.50

Roth Capital Partners downgraded Recro Pharma (NASDAQ:REPH) to “neutral” with a price target of $7.50 after the company received a second complete response letter (CRL) from the FDA about its NDA for meloxicam, an...

March 25, 2019
Nevro
Markets

Canaccord ups Nevro PT to $62 from $46

Canaccord Genuity raised its price target for Nevro (NYSE:NVRO) to $62 from $46 after the medical device maker appointed Keith Grossman as president and CEO, effective immediately. The stock closed at $44.77 on March 19...

March 20, 2019
INmune Bio
Markets

Maxim starts INmune Bio at buy; PT $13

Maxim Group launched coverage of INmune Bio (NASDAQ:INMB) with a “buy” rating and $13 price target. The stock closed at $7.73 on March 18. INmune Bio is a clinical-stage immunotherapy company with three drug programs...

March 19, 2019
Momenta Pharma
Markets

BTIG starts Momenta Pharma at neutral

BTIG launched coverage of Momenta Pharmaceuticals (NASDAQ:MNTA) with a “neutral” rating. The stock closed at $14.15 on March 15. Analyst Thomas Schrader writes that Momenta’s transition from a generics company to a more...

March 18, 2019
InMed Pharma
Markets

Roth starts InMed Pharma at buy; PT $1.10

Roth Capital Partners initiated coverage of InMed Pharmaceuticals (TSX:IN; OTCQX:IMLFF) with a “buy” rating and 12-month price target of $1.10. The stock closed at 57 cents on March 15. InMed is focused on developing...

March 18, 2019